NASDAQ:REXNRexahn Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rexahn Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.45 -0.03 (-1.21 %) (As of 08/13/2020 09:30 AM ET) Add Compare Share Today's Range$2.39Now: $2.45▼$2.6750-Day Range$2.48MA: $2.76▼$3.0052-Week Range$1.26Now: $2.45▼$4.26Volume53,051 shsAverage Volume199,758 shsMarket Capitalization$9.85 millionP/E RatioN/ADividend YieldN/ABeta0.98 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Rexahn Pharmaceuticals. Previous Next 2.4 Community Rank Outperform VotesRexahn Pharmaceuticals has received 107 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRexahn Pharmaceuticals has received 116 “underperform” votes. (Add your “underperform” vote.)Community SentimentRexahn Pharmaceuticals has received 52.02% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote “Outperform” if you believe REXN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe REXN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRexahn Pharmaceuticals does not currently pay a dividend.Dividend GrowthRexahn Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rexahn Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of Rexahn Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 7.28% of the stock of Rexahn Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioRexahn Pharmaceuticals has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:REXN Previous Symbol CUSIPN/A CIK1228627 Webwww.rexahn.com Phone240-268-5300Debt Debt-to-Equity RatioN/A Current Ratio5.70 Quick Ratio5.70Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / Book0.99Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-8,640,000.00 Net MarginsN/A Return on Equity-61.45% Return on Assets-48.12%Miscellaneous Employees10 Outstanding Shares4,019,000Market Cap$9.85 million Next Earnings Date8/19/2020 (Estimated) OptionableOptionable $2.45 -0.03 (-1.21 %) (As of 08/13/2020 09:30 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive REXN News and Ratings via Email Sign-up to receive the latest news and ratings for REXN and its competitors with MarketBeat's FREE daily newsletter. Rexahn Pharmaceuticals (NASDAQ:REXN) Frequently Asked Questions How has Rexahn Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)? Rexahn Pharmaceuticals' stock was trading at $1.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REXN shares have increased by 28.3% and is now trading at $2.45. View which stocks have been most impacted by COVID-19. When is Rexahn Pharmaceuticals' next earnings date? Rexahn Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 19th 2020. View our earnings forecast for Rexahn Pharmaceuticals. How were Rexahn Pharmaceuticals' earnings last quarter? Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.95) by $0.34. View Rexahn Pharmaceuticals' earnings history. When did Rexahn Pharmaceuticals' stock split? How did Rexahn Pharmaceuticals' stock split work? Rexahn Pharmaceuticals shares reverse split before market open on Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 11th 2019. An investor that had 100 shares of Rexahn Pharmaceuticals stock prior to the reverse split would have 8 shares after the split. Has Rexahn Pharmaceuticals been receiving favorable news coverage? Media coverage about REXN stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Rexahn Pharmaceuticals earned a news impact score of -4.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news about Rexahn Pharmaceuticals. Are investors shorting Rexahn Pharmaceuticals? Rexahn Pharmaceuticals saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 364,900 shares, an increase of 254.3% from the January 31st total of 103,000 shares. Based on an average trading volume of 410,400 shares, the days-to-cover ratio is currently 0.9 days. Approximately 9.1% of the company's stock are sold short. View Rexahn Pharmaceuticals' Short Interest. Who are some of Rexahn Pharmaceuticals' key competitors? Some companies that are related to Rexahn Pharmaceuticals include Hoth Therapeutics (HOTH), Q BioMed (QBIO), Annovis Bio (ANVS), Bellicum Pharmaceuticals (BLCM), Ceapro (CRPOF), Guardion Health Sciences (GHSI), Celsion (CLSN), Provectus Biopharmaceuticals (PVCT), Millendo Therapeutics (MLND), Advaxis (ADXS), Neos Therapeutics (NEOS), Sunesis Pharmaceuticals (SNSS), Alimera Sciences (ALIM), Pulmatrix (PULM) and Generex Biotechnology (GNBT). View all competitors. What other stocks do shareholders of Rexahn Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), CorMedix (CRMD), SLS International (SLS), Novavax (NVAX), AcelRx Pharmaceuticals (ACRX), Dynavax Technologies (DVAX), Celsion (CLSN), CytRx (CYTR) and Medallion Financial (MFIN). Who are Rexahn Pharmaceuticals' key executives? Rexahn Pharmaceuticals' management team includes the following people: Douglas J. Swirsky, President, CEO, CFO, Secretary & DirectorD J Kim, Vice President, Head-Research & DevelopmentLisa M. Nolan, Chief Business Officer What is Rexahn Pharmaceuticals' stock symbol? Rexahn Pharmaceuticals trades on the NASDAQ under the ticker symbol "REXN." Who are Rexahn Pharmaceuticals' major shareholders? Rexahn Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.40%). Company insiders that own Rexahn Pharmaceuticals stock include Ben Gil Price, Charles Beever, Douglas J Swirsky and Lisa Nolan. View institutional ownership trends for Rexahn Pharmaceuticals. Which major investors are buying Rexahn Pharmaceuticals stock? REXN stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Rexahn Pharmaceuticals stock in the last two years include Ben Gil Price, Charles Beever, Douglas J Swirsky, and Lisa Nolan. View insider buying and selling activity for Rexahn Pharmaceuticals. How do I buy shares of Rexahn Pharmaceuticals? Shares of REXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Rexahn Pharmaceuticals' stock price today? One share of REXN stock can currently be purchased for approximately $2.45. How big of a company is Rexahn Pharmaceuticals? Rexahn Pharmaceuticals has a market capitalization of $9.85 million. Rexahn Pharmaceuticals employs 10 workers across the globe. What is Rexahn Pharmaceuticals' official website? The official website for Rexahn Pharmaceuticals is www.rexahn.com. How can I contact Rexahn Pharmaceuticals? Rexahn Pharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The company can be reached via phone at 240-268-5300 or via email at [email protected] This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
